{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PK: Cmax of LY3435151 in Combination with Pembrolizumab.","groups":[{"description":"Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.","id":"OG000","title":"10 mg LY3435151"}],"populationDescription":"Zero participants were analyzed. The study was terminated early and no data was collected.","reportingStatus":"POSTED","timeFrame":"Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)","title":"PK: Cmax of LY3435151 in Combination With Pembrolizumab","type":"SECONDARY"}